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Background: The activation of ERK, p38 and JNK signal cascade in host cells has been demonstrated to up-regulate of
enterovirus 71 (EV71)-induced cyclooxygenase-2 (COX-2)/ prostaglandins E2 (PGE2) expression which is essential
for viral replication. So, we want to know whether a compound can inhibit EV71 infection by suppressing COX-2/PGE2
expression.
Methods: The antiviral effect of formononetin was determined by cytopathic effect (CPE) assay and the time course
assays. The influence of formononetin for EV71 replication was determined by immunofluorescence assay, western
blotting assay and qRT-PCR assay. The mechanism of the antiviral activity of formononetin was determined by western
blotting assay and ELISA assay.
Results: Formononetin could reduce EV71 RNA and protein synthesis in a dose-dependent manner. The time course
assays showed that formononetin displayed significant antiviral activity both before (24 or 12 h) and after (0–6 h) EV71
inoculation in SK-N-SH cells. Formononetin was also able to prevent EV71-induced cytopathic effect (CPE) and suppress
the activation of ERK, p38 and JNK signal pathways. Furthermore, formononetin could suppress the EV71-induced
COX-2/PGE2 expression. Also, formononetin exhibited similar antiviral activities against other members of Picornaviridae
including coxsackievirus B2 (CVB2), coxsackievirus B3 (CVB3) and coxsackievirus B6 (CVB6).
Conclusions: Formononetin could inhibit EV71-induced COX-2 expression and PGE2 production via MAPKs pathway
including ERK, p38 and JNK. Formononetin exhibited antiviral activities against some members of Picornaviridae. These
findings suggest that formononetin could be a potential lead or supplement for the development of new anti-EV71
agents in the future.
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Enterovirus 71 (EV71) is a single-stranded, positive-
sense RNA virus belonging to the enterovirus genus of
the Picornaviridae family [1]. EV71 is a common entero-
virus that usually causes hand, foot and mouth disease
in children mostly under 5 years. Most EV71 infections
result in mild clinical symptoms and are self-limiting,
small part EV71 infections is often associated with
neurological diseases include aseptic meningitis, brain
stem encephalitis and acute flaccid paralysis. EV71 was
first isolated from patients with central nervous system
diseases in California in 1969. Since then, outbreaks have
been periodically reported worldwide, especially in the* Correspondence: yuhuanlibj@126.com
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unless otherwise stated.Asia-Pacific region. Hundreds of cases involving lethal
complications have been reported in each outbreak [2,3].
EV71 is neurotropic virus that can cause severe neuro-
logical diseases associated with inducing inflammation in
the CNS region [4,5]. And, some researchs reported that
EV71 infections were related to cyclooxygenase-2 (COX-2)/
prostaglandins E2 (PGE2) pathway [6,7]. Cyclooxygenase
(COX) is the rate-limiting step in the production of prosta-
glandins (PGs) from arachidonic acid. The acute encephal-
itis during virus or bacteria infection is partially mediated
through cyclooxygenase-2 (COX-2)/prostaglandins (PGE2)
expression. It had been reported that the expression of
COX-2 could be observed during some viral infections
including coxsackievirus B3 (CVB3) and theiler’s murineThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that COX-2 expression increased in human and rat nerve
cell with EV71 infection through the action of MAPKs,
NF-kB, and AP-1 and EV71-induced COX-2 expression
and PGE2 production promoted viral replication via
cAMP signaling [6,9]. Moreover, COX-2 expression and
PGE2 generation increased by EV71 might be required
for EV71 viral replication. So, targeting COX-2 and
their upstream signaling components should yield use-
ful therapeutic targets for EV71 intection.
EV71 could cause severe complications and even death
in each outbreak. Unfortunately, currently there is no
approved vaccine or antiviral drug for EV71-induced
disease prevention and therapy. There is a clear need to
develop inhibitors for EV71. There are some compounds
reported exhibited antiviral activity against EV71, such as
pleconaril [10], pyridyl imidazolidinones [11], Ganoderma
lucidum triterpenoids [12], GuiQi [13], 7-Hydroxyflavone
[14], chebulagic acid [15], chlorogenic acid [16], epigallo-
catechin gallate [17], chrysosplenetin [18], penduletin [18],
7-Hydroxyisoflavone [19], chrysin [20], pirodavir [21],
and so on. However, it was just a simple evaluation of
compounds as anti-EV71 agents and there were no in-
depth mechanism researches to be done. So, there is an
urgent need to develop an effective anti-EV71 agent for
the control of EV71 infection.
In a large-scale screening for novel candidates exhibit-
ing activity against EV71, we found that formononetin
was active against EV71 infection (Figure 1C).
Formononetin, a kind of plant isoflavonoids, was
isolated from a number of plants and herbs such as the
red clover. It has been reported to have multi pharma-
cological effects such as anti-inflammatory [3,22,23], anti-
oxidant [24], wound healing [25], antitumor [26,27],
vasorelaxant [28], cardioprotective activies [29] and
neuroprotective activies [30] by regulating the mitogen-
activated protein kinases (MAPKs) including ERK, p38,
c-Jun-N terminal kinase (JNK). However, no antiviral
activity has been reported for formononetin although
some flavonoids and isoflavonoids reported exhibited anti-
EV71 activities such as chrysin [20], 7-Hydroxyflavone
[14], chrysosplenetin [18], penduletin [18] and 7-
Hydroxyisoflavone [19]. Moreover, most compounds
are just a simple evaluation effects as anti-EV71 agents
and researches about the anti-EV71 mechanism of
flavonoids and isoflavonoids had been reported rarely.
Against this background, it would be interesting to
know whether formononetin can influence the pro-
pagation of EV71 by inhibiting EV71-induced COX-2
expression and PGE2 production via MAPKs pathway
including ERK, p38 and JNK. In this study, we evaluated
the antiviral effect of formononetin on EV71 replication in
Vero and SK-N-SH cells. We further explored the mech-
anism of the antiviral activity of formononetin againstEV71. Our findings will shed new light on the design of
anti-EV71 agents for HFMD patients especially those with
neurological complications.
Results
Inhibition of EV71 replication by formononetin
Before detecting the antiviral effect of formononetin
in vitro, we first detected the toxicity of formononetin in
cells. As shown in Table 1, the 50% toxicity concentra-
tion (TC50) of formononetin was 149.38 μmol/L in Vero
cells and 198.80 μmol/L in SK-N-SH cells through the
MTS assay. The maximal non-toxicity dose (TC0) of
formononetin was 41.42 μmol/L in Vero cells and 55.92
μmol/L in SK-N-SH cells through the MTS assay. The
TC50 of pirodavir was 22.33 μmol/L in Vero cells and
30.30 μmol/L in SK-N-SH cells by MTS assay. The TC0
of pirodavir was 7.52 μmol/L in Vero cells and 10.83
μmol/L in SK-N-SH cells through the MTS assay.
The IC50 of formononetin for EV71 SHZH98 strain
was 3.45 μmol/L in Vero cells and 3.98 μmol/L in SK-N-
SH cells. This was much lower than the TC50. The
selectivity index (SI) is 38.11 in Vero cells and 43.07 in
SK-N-SH cells (Table 1). The TC50, IC50 and SI of for-
mononetin for other EV71 strains (JS-52, H and BrCr)
in Vero cells are list in Table 2. These results demon-
strated that formononetin can significantly inhibit the
replication of EV71. Therefore, formononetin was a safe
and effective agent against EV71.
Formononetin can reduce the RNA and protein synthesis
of EV71
To examine the effect of formononetin on the biological
synthesis of EV71, the EV71 (SHZH98 strain) infected
cells was treated with formononetin and pirodavir and
then the VP1 protein was analyzed by Western blotting.
As shown in Figure 2A, formononetin can decrease the
expression of VP1 protein in a dose dependent manner.
The immunofluorescence assay also showed a similar result
(Figure 2B). This result is consistent with the Western
blot detection. Furthermore, formononetin treatment
dose-dependently decreased the levels of EV71 RNA
measured by reverse transcription-quantitative polymerase
chain reaction (RT-qPCR) assay (Figure 2C). Pirodavir can
also decrease the RNA and protein synthesis of EV71.
These results suggested that both formononetin and
pirodavir exhibit effectively anti-EV71 activity.
Time course assay
Time course assay was performed to explore which stage
formononetin and pirodavir function during EV71 repli-
cation. As shown in Figure 1B. We found that treatment
with formononetin at 24 and 12 h before, and 0 to 6 h
after EV71 infection was able to effectively reduce virus-
induced CPE, while it did not exert this effect at −1, 9,
(C)
Figure 1 The chemical structure of formononetin and time course assay. (A) The illustration of the protocol of viral adsorption and treatment
with formononetin and pirodavir. SK-N-SH cells were infected with 80 pfu/well of EV71 (SHZH98). Formononetin (9.21 μM) and pirodavir (0.84 μM) was
added at the indicated times, respectively. (B) The morphological changes of EV71-infected cells treated with or without formononetin and pirodavir
were observed at 48 h post-infection. The cytopathic effect (CPE) assay was shown. (C) The chemical structure of formononetin.
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ment functioned only after viral infection (0–9 h p.i.) ra-
ther than before or during the infection.
Formononetin can inhibit EV71-induced phosphorylation
of ERK, p38 and JNK
It was known that ERK, p38 and JNK were downstream
components of epidermal growth factor receptor (EGFR)
signaling pathways which can be stimulated by several
stimuli including EV71 infection in various cell types
[31-34]. Thus, we assessed whether the EV71-inducedphosphorylation of ERK, p38 and JNK could be reduced
by formononetin. As shown in Figure 3, EV71-stimulated
phosphorylation of ERK, p38 and JNK were significantly at-
tenuated by treatment with formononetin (14.91 μmol/L)
but not pirodavir.
Formononetin can inhibit EV71-induced COX-2 expression
and PGE2 generation
It had been previously described that MAPKs were in-
volved in COX-2 expression induced by EV71 infection
[6]. We found that EV71-stimulated COX-2 expression




TC0 (μmol/L) TC50 (μmol/L) IC50(μmol/L) SI TC0 (μmol/L) TC50 (μmol/L) IC50 (μmol/L) SI
Formononetin 41.42 ± 0 149.38 ± 12.15 3.45 ± 0.55 43.30 55.92 ± 0 198.80 ± 6.02 3.98 ± 0.80 49.95
Pirodavir 7.52 ± 0 22.33 ± 1.71 0.38 ± 0.08 58.76 10.83 ± 0 30.30 ± 4.03 0.23 ± 0.04 131.74
Values provided in this table represent the mean of three independent experiments.
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mononetin (14.91 μmol/L) but not pirodavir (Figure 4A).
PGE2 is a major product of COX-catalyzed arachidonic
acid metabolism and the PGE2 level can act as a marker of
functional activity of COX-2 expression. EV71-induced
the expression of COX-2 was associated with PGE2
production in SK–N–SH cells [6]. Interestingly, EV71-
stimulated PGE2 release in SK–N–SH cells was attenu-
ated by pretreatment with formononetin but not pirodavir
(Figure 4B). These results demonstrated that EV71-
induced COX-2 expression and PGE2 release in SK–N–
SH cells can been attenuated by formononetin but not
pirodavir.Inhibition of CVBs replication by formononetin
Several isoflavonoids were found to exhibit broad-spectrum
antiviral activity against picornaviruses. Thus, we speculated
that formononetin might inhibit CVBs replication. The
CPE reduction assay was used to determine the anti-
CVBs activities of formononetin. Indeed, formononetin
significantly inhibited the biosynthesis of CVB2, CVB6
and CVB3 in Vero cells. The IC50 and therapeutic index
of formononetin for CVBs were showed in Table 2.Discussion
EV71, a member of the Picornaviridae family, causes
HFMD by spreading through contact with virus-containing
body fluids, respiratory droplets, and feces. However, there
is no effective antiviral drug available for the treatment
of HFMD. Some natural medicinal compounds have
demonstrated to be active against the disease by ameli-
orating the symptoms and shortening the course [35,36].Table 2 The efficiency of formononetin against other EV71
strains and CVBs in vitro
TC50 (μmol/L) IC50 (μmol/L) SI
JS-52 149.38 ± 12.15 17.87 ± 8.51 78.36
H 149.38 ± 12.15 11.11 ± 9.23 13.45
BrCr 149.38 ± 12.15 6.47 ± 4.40 23.09
CVB2 149.38 ± 12.15 9.56 ± 2.23 15.63
CVB6 149.38 ± 12.15 5.33 ± 1.48 28.03
CVB3 149.38 ± 12.15 2.57 ± 0.87 58.12
Values provided in this table represent the mean of three independent
experiments.The current absence of antiviral strategies for EV71 high-
light the urgency of developing novel antiviral approaches.
Formononetin, a methoxylated isoflavone, is a main
component in many traditional Chinese medicines such as
Trifolium pratense, Radix Puerariae, Astragalus membra-
naceus, Lignum Dalbergiae Odoriferae, Suberect Spatho-
lobus Stem and Radix hedysari. Previous studies have
indicated that formononetin had many pharmacological
properties such as antioxidative [24], anti-inflammatory
[3,22,23], anticancer activities [26,27], acceleration of
wound repair [25], neuronal protective [30] and cardio-
protective effects [29]. As a phytoestrogen, formonone-
tin also functions in menopause treatment. However,
the antiviral activity of formononetin is rarely reported.
In this study, we evaluated the anti-enterovirus activities
of formononetin.
Picornaviruses are important human pathogens. Up to
now, there is still no specific anti-picornavirus agent
approved for clinical application. Three capsid-targeting
molecules known as “WIN” compounds are currently in
clinical development [37,38]. According to our results
(dates not shown), the antiviral activity of pirodavir against
EV71 is better than pleconaril. Thus, we used pirodavir as
positive control for the evaluation of the antiviral activity
of formononetin.
In the present study, we found that formononetin
could inhibit the EV71-induced CPE in Vero or SK-N-
SH cells. Formononetin could also inhibit viral RNA and
protein synthesis in a dose-dependent manner. Time
course assay in SK-N-SH cells showed that formononetin
acted at an early stage of EV71 infection. The pretreat-
ment with formononetin before infection also effectively
inhibited EV71 replication. These findings demonstrated
that formononetin exhibited strong antiviral activity
against EV71. Moreover, formononetin showed antiviral
activities against CVB2, CVB3 and CVB6. The preliminary
analysis indicated that formononetin could inhibit EV71-
induced COX-2 expression and PGE2 production via
MAPKs pathway including ERK, p38 and JNK.
There are some flavonoids and isoflavonoids reported
exhibited anti-EV71 activities such as chrysin [20], 7-
Hydroxyflavone [14], chrysosplenetin [18], penduletin
[18] and 7-Hydroxyisoflavone [19]. However, most com-
pounds are just a simple evaluation effects as anti-EV71
agents and researchs about the anti-EV71 mechanism of




Figure 2 The antiviral effect of formononetin and pirodavir against EV71 in SK-N-SH cells. (A) Formononetin and pirodavir reduced the
expression of EV71 VP1 protein in SK-N-SH cells by western blot assay. (B) Formononetin and pirodavir reduced the expression of EV71 VP1 protein in
SK-N-SH cells by immunofluorescence assay. Cells were examined using a fluorescence microscopy (×100). (C) Formononetin and pirodavir reduced
the expression of EV71 VP1 RNA by one-step qRT-PCR assay. *P < 0.001 #P < 0.05.




Figure 3 Formononetin but not pirodavir reduces the phosphorylation of ERK (A), p38 (B), and JNK (C) induced by EV71 infection.
SK-N-SH cells (9 × 105 cells/well) were plated into 6-well culture plates. The cells were then pretreated with formononetin (14.91 μmol/L) and
pirodavir (1.08 μmol/L), respectively. After 24 h, the cells were mock-infected or infected with 4.8 × 105 pfu/well of EV71 (SHZH98) for 15 min (A),
10 min (B), and 30 min (C), respectively. The cells were harvested and ERK (A) p-ERK (A), p38 (B), p-p38 (B), JNK (C), and p-JNK (C) were detected
by western blot.
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Figure 4 Formononetin could inhibit EV71-induced COX-2 expression and PGE2 production. (A) Formononetin but not pirodavir can
reduce the expression of COX-2 induced by EV71 infection. SK-N-SH cells were mock-infected or infected with 480 pfu/well of EV71 (SHZH98) for
2 h. The cells were then treated with formononetin (14.91 μmol/L) and pirodavir (1.08 μmol/L), respectively, for 24 h. The cells were harvested
and EV71-VP1 and COX-2 were examined by western blot. (B) Formononetin but not pirodavir can reduce the release of PGE2 stimulated by EV71
infection. SK-N-SH cells were pretreated with formononetin (14.91 μmol/L) or pirodavir (1.08 μmol/L) for 24 h. The cells were infected with 4.8 × 105
pfu/well of EV71 (SHZH98). At 24 h p.i., the culture supernatants were harvested for PGE2 release assay.
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mechanism of formononetin. Also, our research is the
first time to find that flavonoids and isoflavonoids
could inhibit EV71-induced COX-2 expression and
PGE2 production via MAPKs pathway including ERK,
p38 and JNK. Moreover, the selectivity indices (SI) of
formononetin is similar to chrysosplenetin [18] and
penduletin [18], and SI of formononetin is better than
7-Hydroxyisoflavone [19].Overall, our findings provide a new clue for developing
the anti-EV71 drug which acts on inhibition of both viral
replication and inflammatory factors expression. This
may offer hopes in the treatment of HFMD patients with
CNS diseases. However, many questions remain, e.g.,
whether formononetin is effective antiviral therapy agains
EV71 without adverse toxic effects in vivo and whether
the proposed reduction in neurological complications is
due to the reduced expression of COX2/PGE2. We will
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trials in further studies.
Conclusion
In this study, we found that formononetin could inhibit
EV71-induced COX-2 expression and PGE2 production
via MAPKs pathway including ERK, p38 and JNK. For-
mononetin exhibited antiviral activities against some
members of Picornaviridae. These findings suggest that
formononetin could be a potential lead or supplement for
the development of new anti-EV71 agent in the future.
Materials and methods
Cells and viruses
Vero cells were purchased from the American Type
Culture Collection (ATCC), and were cultured in Mini-
mum Essential Medium (MEM) supplemented with 10%
fetal bovine serum (FBS) (GBICO) and antibiotics (100
U/ml penicillin and 100 mg/ml streptomycin). SK-N-SH
cells were also purchased from the ATCC, and were
cultured in Dulbecco’s Modified Eagle Medium: Nutrient
Mixture F-12 (DMEM/F-12) supplemented with 10% FBS
and antibiotics (100 U/ml penicillin G and 100 mg/ml
streptomycin).
EV71 strain SHZH98 isolated from the throat swab
sample of an HFMD case occurring in 1998 in China
was kindly provided by Dr. Qi Jin, Institute of Pathogen
Biology, Chinese Academy of Medical Science and Pe-
king Union Medical School, Beijing, China. EV71 strain
BrCr (VR-1775) and H (VR-1432) were purchased from
the ATCC. EV71 strain JS-52 was a kind gift from Dr.
Xiangzhong Ye, Beijing Wantai Biological Pharmacy
Enterprise Co., Ltd. EV71 strain SHZH98 was passaged
in Vero and SK-N-SH cells. EV71 strains BrCr, H, and
JS-52 were passaged in Vero cells. CVB2 (strain Ohio-1),
CVB3 (strain Nancy) and CVB6 (strain Schmitt) were all
got from the ATCC and passaged in Vero cells.
Compounds
Formononetin was purchased from the J&K Chemical
Ltd. (Beijing, China) and the purity is no less than 99%.
Pirodavir was kindly provided by Professor Junhai
Xiao, Laboratory of Computer-Aided Drug Design &
Discovery, Beijing Institute of Pharmacology & Toxi-
cology, Beijing, China. Both formononetin and pira-
davir were dissolved into DMSO.
Plaque assay for virus titer
Vero cells (3 × 105 cells/well) were plated into 24-well
plate and the cells were infected with 10-fold serially
diluted virus suspension (200 μl/well). Suspension was
diluted in MEM with 2% FBS. After absorption at 37°C
with 5% CO2 for 2 h, the virus suspension was replaced
with MEM containing 2% FBS and 1% methyl cellulose.The medium was removed at 96 h after infection. The
cells were washed with phosphate-buffered saline (PBS),
and then fixed and stained with 5% crystal violet at 37°C
for 1 h. Finally, the crystal violet was washed out with
water and heat-dried at 37°C. The plaques were counted
and virus titer (pfu/ml) was calculated.
Cytotoxicity assay
Cytotoxic effect of formononetin on Vero or SK-N-SH
cells was assayed by MTS (promega) assay. Briefly, cells
(3 × 104 cells/well) were seeded into 96-well culture plates
and were incubated overnight. Then, the medium was
removed and different concentrations of formononetin
were applied in triplicate. After 3 days’ incubation, the
cytotoxicity of formononetin was determined by MTS
assay. The TC50 was defined as the concentration that
inhibits 50% cellular growth in comparison with the
controls and the TC0 was defined as the maximal non-
toxicity dose.
CPE inhibition assay for anti-EV71
The anti-EV71 activity of formononetin was assayed by
CPE inhibition method. Briefly, cells (3 × 104 cells/well)
were plated into 96-well culture plates for incubation of
24 h. The medium was then removed and cells were
infected with EV71 of 80 pfu/well. Then, various con-
centrations of formononetin were supplemented for
incubation of another 48 h. The IC50 defined as the min-
imal concentration of inhibitor required to inhibit 50%
of CPE was determined by Reed & Muench method.
The selectivity index (SI) was calculated as the ratio of
TC50/IC50 [19].
Western blot analysis
Cells were lysed in the M-PER mammalian protein ex-
traction reagent (Thermo, Rockford, IL) containing halt
protease inhibitor single-use cocktail (Thermo). The
protein concentration was determined by the BCA re-
agents (Thermo). About 10 μg proteins were denatured
and applied to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). The electrophoresis
products were transferred to a polyvinyl idenefluoride
(PVDF) film and PVDF membranes were then incubated
at room temperature with specific primary antibody.
After a standard washing, membranes were incubated
with horse radish peroxidase (HRP)-labeled secondary
antibody. The assay developed using a chemiluminescent
substrate. The primary antibodies used in this study in-
cluded antibodies against β-actin, p-p44/p42 MAPK,
p44/p42 MAPK, p-p38 MAPK, p38 MAPK, p-JNK, JNK
(Cell Signaling Technology), EV71 VP1 (Abnova) and
COX-2 (Santa Cruz Biotechnology). The goat anti-rabbit
and anti-mouse HRP-labeled antibodies were obtained
from Cell Signaling Technology.
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SK-N-SH cells grown on glass coverslips (Thermo) were
infected with EV71 (SHZH98) of 160 pfu/well for 2 h.
Then, various concentrations of formononetin were
supplemented for incubation of another 24 h. After
incubation, the culture medium was removed and the
cells were washed and fixed. The cells were perme-
abilized in 0.5% Triton X-100 at room temperature for
15 min and blocked in PBS containing 1% BSA for 60
min at room temperature. Cells were then incubated
with an anti-EV71 VP1 antibody (Abnova) at a dilution
of 1: 500 for 2 h at room temperature. After washing
three times with PBS, the samples were reacted with
Alexa Fluor 488-labeled goat anti-mouse secondary
antibody (Beyotime Institute of Biotechnology, China)
for 1 h at room temperature. After washing with PBS,
images were taken using a fluorescence microscope
(Olympus, IX71) [39].
Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) quantification
SK-N-SH cells (9 × 105cells/well) were plated into 6-well
culture plates for incubation of 16 h. The medium was
removed and cells were infected with EV71 (SHZH98)
of 480 pfu/well. After 2 h, various concentrations of for-
mononetin were supplemented for incubation of another
24 h. The total RNA of the infected cells was extracted
using the RNeasy Mini kit (QIAGEN) according to the
manufacturer’s instructions. The one-step qRT-PCR was
performed with SuperScript III Platinum SYBR Green
One-step RT PCR Kit (Invitrogen) using the ABI 7500
Fast Real-Time PCR system (Applied Biosystems). The
mRNA expression of EV71 VP1 was detected with sense
primer 5’-GCAGCCCAAAAGAACTTCAC-3’ and anti-
sense primer 5’-ATTTCAGCAGCTTGGAGTGC-3’ tar-
geting a conserved region of the VP1 gene [40]. The
β-actin mRNA was detected using sense primers 5’-
TGACGGGGT CACCCACA CTGTGCCCATCTA-3’
and antisense primer 5’-CTAGAAGCATTTG CGGT
GGACG ATG-3’.
Time course assay
The antiviral activity of formononetin was examined at
different time periods before and after viral infection as
shown in Figure 1A. Briefly, cells (3 × 104 cells/well)
were seeded and incubated for 16 h. The cell monolayer
was then infected with EV71 of 80 pfu/well. Different
concentrations of formononetin were supplemented into
cells following the protocol. Cells were then incubated
for another 48 h and assayed with CPE assay.
Measurement of PGE2 release
For the detection of PGE2 release, SK–N–SH cells (3 × 10
5
cells/well) were seeded into 24-well culture plates andwere incubated for 16 h. And then the cells were
serum-deprived for 24 h and incubated with EV71 for
the indicated time intervals. When drugs were used,
they were added 24 h prior to the application of EV71.
After treatment, the supernatants were harvested. The
supernatant from each sample was assayed using a
PGE2 EIA kit (AMEKO) following the manufacturer’s
instruction. Briefly, we added sample, and successively
anti-PGE2 antibody, streptavidin-HRP to the plate. The
plate was closed with closure plate membrane and incu-
bated for 60 min at 37°C. After uncovering closure plate
membrane, liquid was discarded and the plate was
washed with washing buffer for 5 times. The chromogen
solution A and B were added to each well and incubated
for 10 min at 37°C. The stop solution was then added to
each well to stop the reaction. The absorbance of each
well was measured at 450 nm [6].CPE inhibition assay for anti-CVBs
The anti-virus activity of formononetin on CVBs was
also assayed by CPE method. Briefly, cells (3 × 104 cells/
well) were plated into 96-well culture plates for incuba-
tion of 24 h. The medium was removed and cells were
infected with 100 TCID50 of CVB2, CVB6 or CVB3.
Then, various concentrations of formononetin were sup-
plemented for incubation of another 48 h. The IC50 was
determined by Reed and Muench method. The SI was
calculated as the ratio of TC50/IC50 [19].
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